首页> 外文期刊>Advances in Nanoparticles >Lipopolysaccharide Modified Liposomes for Amyotropic Lateral Sclerosis Therapy: Efficacy in SOD1 Mouse Model
【24h】

Lipopolysaccharide Modified Liposomes for Amyotropic Lateral Sclerosis Therapy: Efficacy in SOD1 Mouse Model

机译:脂多糖修饰的脂质体对肌萎缩性侧索硬化症的治疗:SOD1小鼠模型的功效。

获取原文
           

摘要

Activation of microglia is a histological feature observed in neurodegenerative diseases like ALS. The oral administration of minocycline has been demonstrated to have minimal neuroprotection ability in the animal models and is also associated with inadvertent toxicity due to non-specific oral absorption of the drug. Nonetheless, the drug itself shows promise in a number of disease models suggesting it could be effective if delivered optimally. Thus, we utilized LPS modified liposomes to target TLR4 receptor on the microglia in SOD1G93A mice and compared its efficacy with non- targeted nanoliposomes. The in vitro results indicate that targeting the TLR4 receptor on microglia significantly increases (p G93A mouse model of ALS, targeted and non-targeted minocycline treatment significantly increased (p G93A mice, the non- targeted nanovesicles significantly increased the latency to rotarod failure and both targeted and non-targeted nanovesicles significantly delayed disease endpoints.
机译:小胶质细胞的激活是在神经退行性疾病(如ALS)中观察到的组织学特征。在动物模型中,口服米诺环素已被证明具有最小的神经保护能力,并且由于药物的非特异性口服吸收,还与无意中的毒性有关。尽管如此,该药物本身在许多疾病模型中都显示出了希望,表明如果以最佳方式给药可能有效。因此,我们利用LPS修饰的脂质体靶向SOD1G93A小鼠小胶质细胞上的TLR4受体,并将其功效与非靶向纳米脂质体进行了比较。体外结果表明,靶向小胶质细胞上的TLR4受体显着增加(ALS的p G93A小鼠模型,米诺环素的靶向和非靶向治疗显着增加(p G93A小鼠,非靶向的纳米囊泡显着增加了轮状细胞衰竭的潜伏期,并且靶向和非靶向纳米囊泡显着延迟了疾病终点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号